Hughes Eric A
Executive VP Global R&D and Chief Med Officer at TEVA
- Sold, on record
- $7.5M
- Dollars the filings state
- Form 4 sales
- 11
- Latest Aug 3, 2026
- Form 144 notices
- 9
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- TEVATEVA PHARMACEUTICAL INDUSTRIES LTDExecutive VP Global R&D and Chief Med Officer
Sales by reason
Form 4 sales per year, every sale on record.
Timeline
- 1 Form 144 notice TEVANoticeMar 3, 2026 2026
Filed to sell 80,762 shares ($2.6M)
Hughes Eric A, Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER
10b5-1 plan3.3x usual sizeFiling
- 2 Form 4 sale TEVAUnusualMar 3, 2026 same day
Sold 80,762 shares at $32.36 ($2.6M)
Hughes Eric A, "See ""Remarks"""
10b5-1 planSold 48.5% of holdings ($5.4M position)85,616 shares left3.3x usual sizeFollows a Form 144Filing
- 3 Form 144 notice TEVANoticeMar 4, 2026 +1 day
Filed to sell 11,277 shares ($366k)
Hughes Eric A, Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER
10b5-1 plan0.5x usual sizeFiling
- 4 Form 4 sale TEVARoutineMar 4, 2026 same day
Sold 11,277 shares at $32.46 ($366k)
Hughes Eric A, "See ""Remarks"""
10b5-1 planSold 10.4% of holdings ($3.5M position)97,590 shares left0.5x usual sizeFollows a Form 144Filing
- 5 Form 144 notice TEVANoticeMar 5, 2026 +1 day
Filed to sell 9,533 shares ($302k)
Hughes Eric A, Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER
10b5-1 plan0.4x usual sizeFiling
- 6 Form 4 sale TEVARoutineMar 5, 2026 same day
Sold 9,533 shares at $31.67 ($302k)
Hughes Eric A, "See ""Remarks"""
10b5-1 planSold 8.1% of holdings ($3.7M position)107,711 shares left0.4x usual sizeFollows a Form 144Filing
- 7 Form 144 notice TEVANoticeAug 3, 2026 +151 days
Filed to sell 25,578 shares ($892k)
Hughes Eric A, Executive VP Global R&D and Chief Med Officer
10b5-1 plan1x usual sizeFiling
- 8 Form 4 sale TEVARoutineAug 3, 2026 same day
Sold 25,578 shares at $34.88 ($892k)
Hughes Eric A, "See ""Remarks"""
10b5-1 planSold 15.9% of holdings ($5.6M position)134,877 shares left1x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (20)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Aug 5, 2026 | TEVA | "See ""Remarks""" | Form 4 sale | 25,578 | $892k | 15.9% | Routine | SEC |
| Aug 3, 2026 | Aug 3, 2026 | TEVA | Executive VP Global R&D and Chief Med Officer | Form 144 notice | 25,578 | $892k | Notice | SEC | |
| Mar 5, 2026 | Mar 9, 2026 | TEVA | "See ""Remarks""" | Form 4 sale | 9,533 | $302k | 8.1% | Routine | SEC |
| Mar 5, 2026 | Mar 5, 2026 | TEVA | Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | Form 144 notice | 9,533 | $302k | Notice | SEC | |
| Mar 4, 2026 | Mar 6, 2026 | TEVA | "See ""Remarks""" | Form 4 sale | 11,277 | $366k | 10.4% | Routine | SEC |
| Mar 4, 2026 | Mar 4, 2026 | TEVA | Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | Form 144 notice | 11,277 | $366k | Notice | SEC | |
| Mar 3, 2026 | Mar 5, 2026 | TEVA | "See ""Remarks""" | Form 4 sale | 80,762 | $2.6M | 48.5% | Unusual | SEC |
| Mar 3, 2026 | Mar 3, 2026 | TEVA | Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | Form 144 notice | 80,762 | $2.6M | Notice | SEC | |
| Aug 1, 2025 | Aug 5, 2025 | TEVA | "See ""Remarks""" | Form 4 sale | 52,742 | $800k | 100.0% | Routine | SEC |
| Aug 1, 2025 | Aug 1, 2025 | TEVA | Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | Form 144 notice | 52,742 | $799k | Notice | SEC | |
| Mar 5, 2025 | Mar 6, 2025 | TEVA | "See ""Remarks""" | Form 4 sale | 23,251 | $367k | 100.0% | Routine | SEC |
| Mar 4, 2025 | Mar 5, 2025 | TEVA | "See ""Remarks""" | Form 4 sale | 24,900 | $400k | 100.0% | Routine | SEC |
| Mar 4, 2025 | Mar 4, 2025 | TEVA | Officer, EXECUTIVE VP GLOBAL R AND D CHIEF MEDICAL OFFICER | Form 144 notice | 23,251 | $372k | Notice | SEC | |
| Mar 3, 2025 | Mar 3, 2025 | TEVA | Officer, EXECUTIVE VP GLOBAL R & D CHIEF MEDICAL OFFICER | Form 144 notice | 24,900 | $410k | Notice | SEC | |
| Aug 12, 2024 | Aug 12, 2024 | TEVA | Officer, EXECUTIVE VP GLBL R AND D AND CHIEF MED OFF | Form 144 notice | 45,060 | $783k | Notice | SEC | |
| Aug 9, 2024 | Aug 13, 2024 | TEVA | "See ""Remarks""" | Form 4 sale | 45,060 | $783k | 100.0% | Unusual | SEC |
| Aug 1, 2024 | Aug 5, 2024 | TEVA | "See ""Remarks""" | Form 4 sale | 24,537 | $423k | 35.3% | Routine | SEC |
| Aug 1, 2024 | Aug 1, 2024 | TEVA | Officer, EXECUTIVE VP GLBL R AND D AND CHIEF MED OFF | Form 144 notice | 24,537 | $423k | Notice | SEC | |
| Mar 4, 2024 | Mar 5, 2024 | TEVA | "See ""Remarks""" | Form 4 sale | 8,045 | $107k | 32.3% | Routine | SEC |
| Aug 1, 2023 | Aug 3, 2023 | TEVA | "See ""Remarks""" | Form 4 sale | 52,742 | $438k | 100.0% | Routine | SEC |